{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coagulopathies&page=4", "query": { "condition": "Coagulopathies", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 891, "total_pages": 90, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coagulopathies&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coagulopathies&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T04:51:30.110Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01598831", "title": "Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Sepsis", "Coagulopathy" ], "interventions": [ { "name": "ART-123", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asahi Kasei Pharma America Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 816, "start_date": "2012-10-29", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 22, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Atlanta, Georgia + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598831" }, { "nct_id": "NCT00301912", "title": "Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-10-02", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301912" }, { "nct_id": "NCT01098487", "title": "A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "Eltrombopag olamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2010-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-03-12", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098487" }, { "nct_id": "NCT01580293", "title": "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "BAY94-9027", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 145, "start_date": "2012-04-23", "completion_date": "2019-11-21", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 14, "location_summary": "Tucson, Arizona • Sacramento, California • San Diego, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01580293" }, { "nct_id": "NCT03741881", "title": "A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Haemophilia A", "Haemophilia A With Inhibitors", "Haemophilia B", "Haemophilia B With Inhibitors" ], "interventions": [ { "name": "No treatment given", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "MALE", "summary": "12 Years and older · Male only" }, "enrollment_count": 231, "start_date": "2018-12-18", "completion_date": "2021-10-25", "has_results": false, "last_update_posted_date": "2021-11-23", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 29, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03741881" }, { "nct_id": "NCT00750009", "title": "Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 583, "start_date": "2008-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00750009" }, { "nct_id": "NCT00049634", "title": "Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-16", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049634" }, { "nct_id": "NCT05044845", "title": "Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gene Therapy", "Hemophilia B" ], "interventions": [ { "name": "Interview", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 150, "start_date": "2022-01-18", "completion_date": "2025-10-14", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05044845" }, { "nct_id": "NCT03432520", "title": "Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "SPK-8011", "type": "GENETIC" }, { "name": "SPK-8016", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Spark Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 29, "start_date": "2018-08-14", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 9, "location_summary": "Boston, Massachusetts • Madison, Mississippi • Kansas City, Missouri + 5 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Madison", "state": "Mississippi" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03432520" }, { "nct_id": "NCT04200456", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immune Thrombocytopenia" ], "interventions": [ { "name": "Rozanolixizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2020-01-31", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-10-04T04:51:30.110Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04200456" } ] }